论文部分内容阅读
目的:探讨缬沙坦对原发性高血压(EH)并心房颤动(Af)患者血清基质金属蛋白酶-2(MMP-2)与组织金属蛋白酶抑制因子-2(TIMP-2)水平的影响。方法:采用定量酶联免疫吸附试验(ELISA)测定28例EH并Af患者(EH并Af组)与30例正常人(正常对照组)血清MMP-2、TIMP-2水平。结果:EH并Af患者MMP-2明显高于正常对照组[(389.58±117.16)∶(291.80±104.15)μg/L,P<0.01],而TIMP-2较正常对照组低[(61.94±27.09)∶(115.22±45.00)μg/L,P<0.01]。EH并Af患者应用缬沙坦治疗6个月后,血清MMP-2水平明显降低(P<0.001),而血清TIMP-2升高(P<0.05)。结论:缬沙坦可降低EH并Af患者血清MMP-2水平,升高TIMP-2水平升高。
Objective: To investigate the effects of valsartan on serum levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-2 (TIMP-2) in patients with essential hypertension (EH) and atrial fibrillation (Af) Methods: Serum levels of MMP-2 and TIMP-2 were measured in 28 patients with EH and Af (EH and Af group) and 30 healthy controls (normal control group) by quantitative enzyme-linked immunosorbent assay (ELISA) Results: The levels of MMP-2 in EH and Af patients were significantly higher than those in normal controls [(389.58 ± 117.16) vs (291.80 ± 104.15) μg / L, P <0.01] ): (115.22 ± 45.00) μg / L, P <0.01]. After 6 months of valsartan treatment in EH and Af patients, serum MMP-2 level was significantly lower (P <0.001), while serum TIMP-2 was higher (P <0.05). Conclusion: Valsartan can reduce serum MMP-2 and increase the level of TIMP-2 in patients with EH and Af.